What are Dr. Geffen’s credentials?

 

Q: What are Dr. Geffen's credentials?

Dr. Jeremy Geffen is a summa cum laude graduate of Columbia University and received his medical degree with honors from New York University School of Medicine. He completed residency training in internal medicine at the University of California at San Diego Medical Center and fellowship training in hematology and oncology at the University of California at San Francisco Medical Center. In 1995 he was elected a Fellow of the American College of Physicians. In addition to his academic medical education and training, Dr. Geffen has traveled extensively and has more than 30 years of experience exploring the great spiritual and healing traditions of the world.

Dr. Geffen founded the Geffen Cancer Center and Research Institute in Vero Beach, Fla., in 1994, which he directed until 2003. It was renowned for its groundbreaking Seven Levels of Healing program. Dr. Geffen practiced medical oncology and hematology for 11 years before closing the center and leaving clinical practice. During his career as a practicing physician he provided guidance and care to thousands of patients and their loved ones.

Dr. Geffen is the author of the highly acclaimed book The Journey Through Cancer: Healing and Transforming the Whole Person. He is founder of Geffen Visions International and also serves as an advisor for P4 Healthcare and Caring4Cancer.com. You can read more about Dr. Geffen here.

<See All FAQs>


Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health